Balance Sheet United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-11 EDT			5-day change	1st Jan Change
346.19 ^USD	+1.09%		-2.03%	+57.44%

09-05	Transcript : United Therapeutics Corporation Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 08:00 AM
09-04	United Therapeutics Insider Sold Shares Worth $2,821,050, According to a Recent SEC Filing	MT

fc1d.o__O4G93l5seo0qqteZ6FpDZoxrwjejGU7EYTcYOrRo.55GFqzg90OJUmj3t8LlXe-iJm0iD26ajZshXDKdp3VfmmbeRBALA3EvgPQ

Published financial data: UNITED THERAPEUTICS CORPORATION

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	1.45B	1.48B	1.69B	1.94B	2.33B
Other Revenues, Total	-	-	-	-	-
Total Revenues	1.45B	1.48B	1.69B	1.94B	2.33B
Cost of Goods Sold, Total	118M	108M	122M	152M	258M
Gross Profit	1.33B	1.38B	1.56B	1.78B	2.07B
Selling General & Admin Expenses, Total	335M	426M	466M	473M	476M
R&D Expenses	1.17B	358M	410M	323M	408M
Other Operating Expenses, Total	1.51B	784M	876M	796M	884M
Operating Income	-178M	591M	687M	989M	1.19B
Interest Expense, Total	-44.2M	-23.5M	-18.6M	-32.4M	-59.3M
Interest And Investment Income	44.2M	28.6M	16.7M	45.2M	163M
Net Interest Expenses	0	5.1M	-1.9M	12.8M	103M
Other Non Operating Income (Expenses)	-	2.8M	-7M	-74.2M	-27.3M
EBT, Excl. Unusual Items	-178M	599M	678M	928M	1.26B
Merger & Related Restructuring Charges	-	-	-	-	-
Gain (Loss) On Sale Of Investments	21.4M	41.5M	48.5M	34.2M	15.8M
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Asset Writedown	-8.8M	-	-133M	-11.2M	-3.6M
Other Unusual Items	-	-1.5M	-	-	-
EBT, Incl. Unusual Items	-165M	639M	594M	951M	1.27B
Income Tax Expense	-60.5M	124M	118M	223M	290M
Earnings From Continuing Operations	-104M	515M	476M	727M	985M
Net Income to Company	-104M	515M	476M	727M	985M
Net Income - (IS)	-104M	515M	476M	727M	985M
Net Income to Common Incl Extra Items	-104M	515M	476M	727M	985M
Net Income to Common Excl. Extra Items	-104M	515M	476M	727M	985M
Per Share Items
Net EPS - Basic	-2.39	11.65	10.6	15.98	21.04
Basic EPS - Continuing Operations	-2.39	11.65	10.6	15.98	21.04
Basic Weighted Average Shares Outstanding	43.8M	44.2M	44.9M	45.5M	46.8M
Net EPS - Diluted	-2.39	11.54	10.06	15	19.81
Diluted EPS - Continuing Operations	-2.39	11.54	10.06	15	19.81
Diluted Weighted Average Shares Outstanding	43.8M	44.6M	47.3M	48.5M	49.7M
Normalized Basic EPS	-2.53	8.47	9.44	12.74	16.85
Normalized Diluted EPS	-2.53	8.39	8.96	11.95	15.87
American Depositary Receipts Ratio (ADR)	0.05	0.05	0.05	0.05	0.05
Supplemental Items
EBITDA	-132M	641M	737M	1.04B	1.24B
EBITA	-177M	591M	687M	989M	1.19B
EBIT	-178M	591M	687M	989M	1.19B
EBITDAR	-127M	644M	740M	1.05B	1.24B
Total Revenues (As Reported)	1.45B	1.48B	1.69B	-	-
Effective Tax Rate - (Ratio)	36.67	19.42	19.89	23.49	22.72
Current Domestic Taxes	72.5M	135M	137M	274M	354M
Current Foreign Taxes	-	-	-	-	-
Total Current Taxes	72.5M	135M	137M	274M	354M
Deferred Domestic Taxes	-133M	-10.5M	-18.8M	-50.8M	-64.4M
Deferred Foreign Taxes	-	-	-	-	-
Total Deferred Taxes	-133M	-10.5M	-18.8M	-50.8M	-64.4M
Normalized Net Income	-111M	374M	424M	580M	789M
Interest on Long-Term Debt	44.2M	-	18.6M	32.4M	59.3M
Non-Cash Pension Expense	-1.2M	2.6M	1.6M	1.9M	-3.5M
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	1.18B	358M	540M	323M	408M
Net Rental Expense, Total	4.9M	3.5M	3.6M	4.8M	5.7M
Imputed Operating Lease Interest Expense	3.14M	788K	662K	1.52M	3.53M
Imputed Operating Lease Depreciation	1.76M	2.71M	2.94M	3.28M	2.17M
Stock-Based Comp., COGS (Total)	200K	7.1M	5.8M	4.9M	2.4M
Stock-Based Comp., R&D Exp. (Total)	400K	29.5M	24.4M	23.8M	15.6M
Stock-Based Comp., SG&A Exp. (Total)	44.8M	127M	108M	78.1M	21.1M
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	45.4M	164M	138M	107M	39.1M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	738M	739M	895M	961M	1.21B
Short Term Investments	748M	1.1B	1.04B	1.88B	1.79B
Total Cash And Short Term Investments	1.49B	1.84B	1.93B	2.84B	2.99B
Accounts Receivable, Total	151M	157M	199M	220M	279M
Other Receivables	-	-	-	70M	21M
Total Receivables	151M	157M	199M	290M	300M
Inventory	93.4M	86.5M	93.8M	102M	112M
Other Current Assets, Total	134M	88.3M	100M	149M	145M
Total Current Assets	1.86B	2.17B	2.32B	3.38B	3.55B
Gross Property Plant And Equipment	1.01B	1.04B	1.12B	1.24B	1.47B
Accumulated Depreciation	-269M	-309M	-342M	-383M	-428M
Net Property Plant And Equipment	743M	732M	781M	862M	1.05B
Long-term Investments	854M	1.23B	1.68B	1.34B	1.94B
Goodwill	28M	28M	28M	28M	33.7M
Other Intangibles, Total	130M	130M	16.6M	16.5M	80.5M
Deferred Tax Assets Long-Term	230M	239M	262M	328M	395M
Deferred Charges Long-Term	9.3M	9.3M	6.9M	10.5M	-
Other Long-Term Assets, Total	54.5M	75.8M	70.2M	75.3M	123M
Total Assets	3.91B	4.62B	5.17B	6.04B	7.17B
Liabilities
Accounts Payable, Total	9.9M	4.1M	3.8M	4.1M	5.6M
Accrued Expenses, Total	181M	299M	291M	326M	358M
Current Portion of Long-Term Debt	250M	-	-	-	400M
Current Portion of Leases	1.8M	2.9M	3.1M	3.9M	4.7M
Other Current Liabilities	20.3M	17.5M	7.1M	9.1M	35.8M
Total Current Liabilities	463M	323M	305M	343M	804M
Long-Term Debt	600M	800M	800M	800M	300M
Long-Term Leases	3M	17.1M	15.8M	27.8M	28.1M
Pension & Other Post Retirement Benefits	38.6M	49.5M	48.9M	32M	18.3M
Other Non Current Liabilities	28.4M	29.9M	40.1M	44.8M	31.4M
Total Liabilities	1.13B	1.22B	1.21B	1.25B	1.18B
Common Stock, Total	700K	700K	700K	700K	700K
Additional Paid In Capital	2.05B	2.15B	2.25B	2.39B	2.55B
Retained Earnings	3.33B	3.84B	4.32B	5.04B	6.03B
Treasury Stock	-2.58B	-2.58B	-2.58B	-2.58B	-2.58B
Comprehensive Income and Other	-14.2M	-14.2M	-23M	-55.5M	-12.8M
Total Common Equity	2.78B	3.4B	3.96B	4.8B	5.98B
Total Equity	2.78B	3.4B	3.96B	4.8B	5.98B
Total Liabilities And Equity	3.91B	4.62B	5.17B	6.04B	7.17B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	43.88M	44.54M	45.13M	46.3M	47.06M
ECS Total Common Shares Outstanding	43.88M	44.51M	45.11M	46.03M	47.04M
Book Value / Share	63.36	76.28	87.77	104.2	127.23
Tangible Book Value	2.62B	3.24B	3.91B	4.75B	5.87B
Tangible Book Value Per Share	59.75	72.73	86.78	103.24	124.8
Total Debt	855M	820M	819M	832M	733M
Net Debt	-1.4B	-2.16B	-2.76B	-3.32B	-4.17B
Debt Equivalent of Unfunded Proj. Benefit Obligation	56.1M	68.6M	67.1M	51.5M	48.8M
Debt Equivalent Oper. Leases	39.2M	28M	28.8M	38.4M	45.6M
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	21.1M	18.4M	17.6M	18M	21.7M
Inventories - Work In Process, Total	29.1M	29.5M	31.9M	33.3M	34.4M
Inventories - Finished Goods, Total	43.2M	38.6M	44.3M	50.7M	55.7M
Land - (BS)	74.4M	74.9M	133M	143M	148M
Buildings, Total	573M	594M	613M	637M	685M
Machinery, Total	318M	325M	323M	354M	381M
Full Time Employees	920	950	965	985	1.17K

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	-104M	515M	476M	727M	985M
Depreciation & Amortization - CF	45.7M	49.7M	49.8M	51.2M	52.9M
Amortization of Goodwill and Intangible Assets - (CF)	200K	200K	100K	100K	300K
Depreciation & Amortization, Total	45.9M	49.9M	49.9M	51.3M	53.2M
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-	9.1M	-90.3M	-5.4M	-
Asset Writedown & Restructuring Costs	17.2M	5.4M	133M	11.2M	3.6M
Stock-Based Compensation (CF)	45.4M	164M	138M	107M	39.1M
Tax Benefit from Stock Options	-	-	-	-	-
Other Operating Activities, Total	-29.7M	-47M	65.9M	52.5M	-4.9M
Change In Accounts Receivable	24.4M	-6M	-41.3M	-21.7M	-58.5M
Change In Inventories	12.9M	10.3M	-7.5M	-13.4M	-13.6M
Change In Accounts Payable	-16.3M	38.6M	-12.5M	44.5M	57.1M
Change in Other Net Operating Assets	-202M	16.8M	-113M	-151M	-82.8M
Cash from Operations	-207M	756M	598M	802M	978M
Capital Expenditure	-83.7M	-59.3M	-121M	-139M	-230M
Sale of Property, Plant, and Equipment	-	2.4M	-	-	-
Cash Acquisitions	-	-	-	-	-89.2M
Divestitures	-12.5M	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-239M	-682M	-366M	-676M	-377M
Other Investing Activities, Total	-	-	-	3.5M	-23M
Cash from Investing	-335M	-738M	-487M	-812M	-720M
Short Term Debt Issued, Total	-	-	-	-	-
Long-Term Debt Issued, Total	800M	-	-	800M	-
Total Debt Issued	800M	-	-	800M	-
Short Term Debt Repaid, Total	-	-	-	-	-
Long-Term Debt Repaid, Total	-200M	-50M	-	-800M	-100M
Total Debt Repaid	-200M	-50M	-	-800M	-100M
Issuance of Common Stock	14M	38.5M	55.6M	94.3M	105M
Repurchase of Common Stock	-2.1M	-3.7M	-10.8M	-11.4M	-13.8M
Other Financing Activities, Total	-700K	-1.7M	-	-7.5M	-2.7M
Cash from Financing	611M	-16.9M	44.8M	75.4M	-11.9M
Foreign Exchange Rate Adjustments	-	-	-	-	-
Net Change in Cash	69.2M	300K	156M	66.4M	246M
Supplemental Items
Cash Interest Paid	41M	20.7M	16.2M	29.1M	56M
Cash Income Tax Paid (Refund)	120M	92.8M	153M	276M	332M
Levered Free Cash Flow	-223M	663M	404M	502M	607M
Unlevered Free Cash Flow	-195M	678M	415M	523M	644M
Change In Net Working Capital	91.9M	-154M	81.7M	115M	-41.2M
Net Debt Issued / Repaid	600M	-50M	-	0	-100M

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	-3.04	8.66	8.78	11.02	11.22
Return on Total Capital	-3.33	9.42	9.57	11.9	12.04
Return On Equity %	-3.75	16.67	12.94	16.61	18.27
Return on Common Equity	-3.75	16.67	12.94	16.61	18.27
Margin Analysis
Gross Profit Margin %	91.88	92.71	92.73	92.17	88.94
SG&A Margin	23.12	28.75	27.65	24.42	20.45
EBITDA Margin %	-9.09	43.21	43.71	53.73	53.24
EBITA Margin %	-12.24	39.86	40.76	51.08	50.97
EBIT Margin %	-12.26	39.84	40.75	51.08	50.96
Income From Continuing Operations Margin %	-7.21	34.71	28.23	37.56	42.31
Net Income Margin %	-7.21	34.71	28.23	37.56	42.31
Net Avail. For Common Margin %	-7.21	34.71	28.23	37.56	42.31
Normalized Net Income Margin	-7.66	25.24	25.14	29.94	33.89
Levered Free Cash Flow Margin	-15.39	44.69	23.94	25.95	26.09
Unlevered Free Cash Flow Margin	-13.48	45.68	24.63	26.99	27.68
Asset Turnover
Asset Turnover	0.4	0.35	0.34	0.35	0.35
Fixed Assets Turnover	2.01	2.02	2.23	2.36	2.44
Receivables Turnover (Average Receivables)	8.86	9.61	9.47	9.24	9.32
Inventory Turnover (Average Inventory)	1.21	1.2	1.36	1.55	2.41
Short Term Liquidity
Current Ratio	4.03	6.7	7.61	9.85	4.41
Quick Ratio	3.54	6.16	6.97	9.12	4.09
Operating Cash Flow to Current Liabilities	-0.45	2.34	1.96	2.34	1.22
Days Sales Outstanding (Average Receivables)	41.2	38.1	38.56	39.5	39.15
Days Outstanding Inventory (Average Inventory)	301.68	304.55	268.61	235.71	151.53
Average Days Payable Outstanding